• 

• CAS 138614-30-9 HOE-140

  Description Although it is a rare disease, HAE is an autosomal dominant disorder that can be potentially life-threatening when swelling manifests itself within the upper airways. Antagonism of the constitutively expressed B2 receptor, therefore, would not only be beneficial in the treatment of HAE but also find application in inflammatory, allergic, and hyperalgesic disorders.Designed to possess enhanced metabolic stability with the inclusion of five non-proteinogenic amino acids, icatibant is a competitive and selective B2 receptor antagonist (devoid of activity against the inducible B1 receptor) with a Ki of 2.2±0.7 nM, and it is the first downstream targeting agent to receive regulatory approval. It joins purified C1 esterase inhibitor, danazol (an attenuated androgen), and tranexamic acid (an antifibrinolytic agent) as acute and prophylactic treatments for HAE.

  Uses Antagonist (bradykinin).

  Uses Icatibant Acetate is a bradykinin B2 receptor antagonist that has been recently approved for treatment of acute attacks of hereditary angioedema (HAE).

  
  

  Price on request

  REQUEST NOW

Product Introduction:

Product Name: HOE-140

Synonyms: HOE-140 (Icatibant);HOE140; ICATIBANT;HOE 140;CS-1399;Firazyr;HOE 140 SYNTHETIC >99% SELECTIVE B2 BRAD YKIN;d-arg-l-arg-l-pro-l-hyp-gly-l-(2-thienyl)ala-l-ser-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2α,3β,7aβ)-octahydro-1h-indole-2-carbonyl-l-arg;Icatibant acetate, D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg;HOE 140 Acetate

CAS: 138614-30-9

MF: C59H89N19O13S.C2H4O2

MW: 1364.59

EINECS: 206-141-6